Literature DB >> 20100990

Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice.

Banumathi K Cole1, Susanna R Keller, Runpei Wu, Jeffrey D Carter, Jerry L Nadler, Craig S Nunemaker.   

Abstract

Obesity, hypertension, cardiovascular disease, and inflammation are closely associated with the rising incidence of diabetes mellitus. One pharmacological target that may have significant potential to lower the risk of obesity-related diseases is the angiotensin type 1 receptor (AT1R). We examined the hypothesis that the AT1R blocker valsartan reduces the metabolic consequences and inflammatory effects of a high-fat (Western) diet in mice. C57BL/6J mice were treated by oral gavage with 10 mg/kg per day of valsartan or vehicle and placed on either a standard chow or Western diet for 12 weeks. Western diet-fed mice given valsartan had improved glucose tolerance, reduced fasting blood glucose levels, and reduced serum insulin levels compared with mice fed a Western diet alone. Valsartan treatment also blocked Western diet-induced increases in serum levels of the proinflammatory cytokines interferon-gamma and monocyte chemotactic protein 1. In the pancreatic islets, valsartan enhanced mitochondrial function and prevented Western diet-induced decreases in glucose-stimulated insulin secretion. In adipose tissue, valsartan reduced Western diet-induced macrophage infiltration and expression of macrophage-derived monocyte chemotactic protein 1. In isolated adipocytes, valsartan treatment blocked or attenuated Western diet-induced changes in expression of several key inflammatory signals: interleukin 12p40, interleukin 12p35, tumor necrosis factor-alpha, interferon-gamma, adiponectin, platelet 12-lipoxygenase, collagen 6, inducible NO synthase, and AT1R. Our findings indicate that AT1R blockade with valsartan attenuated several deleterious effects of the Western diet at the systemic and local levels in islets and adipose tissue. This study suggests that AT1R blockers provide additional therapeutic benefits in the metabolic syndrome and other obesity-related disorders beyond lowering blood pressure.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20100990      PMCID: PMC2836256          DOI: 10.1161/HYPERTENSIONAHA.109.148049

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  39 in total

1.  Effects of angiotensin II type 1 receptor blockade on beta-cell function in humans.

Authors:  Syed Bokhari; Zarmen Israelian; Jonelle Schmidt; Eliot Brinton; Christian Meyer
Journal:  Diabetes Care       Date:  2007-01       Impact factor: 19.112

Review 2.  The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?

Authors:  Stefan Engeli; Petra Schling; Kerstin Gorzelniak; Michael Boschmann; Jürgen Janke; Gérard Ailhaud; Michèle Teboul; Florence Massiéra; Arya M Sharma
Journal:  Int J Biochem Cell Biol       Date:  2003-06       Impact factor: 5.085

3.  Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors.

Authors:  Jürgen Janke; Stefan Engeli; Kerstin Gorzelniak; Friedrich C Luft; Arya M Sharma
Journal:  Diabetes       Date:  2002-06       Impact factor: 9.461

4.  Vasoactive drugs enhance pancreatic islet blood flow, augment insulin secretion and improve glucose tolerance in female rats.

Authors:  Zhen Huang; Leif Jansson; Ake Sjöholm
Journal:  Clin Sci (Lond)       Date:  2007-01       Impact factor: 6.124

5.  Effects of telmisartan on fat distribution in individuals with the metabolic syndrome.

Authors:  Michio Shimabukuro; Hideaki Tanaka; Takeshi Shimabukuro
Journal:  J Hypertens       Date:  2007-04       Impact factor: 4.844

6.  Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action.

Authors:  Paresh Dandona; Vikramjeet Kumar; Ahmad Aljada; Husam Ghanim; Tufail Syed; Debborah Hofmayer; Priya Mohanty; Devjit Tripathy; Rajesh Garg
Journal:  J Clin Endocrinol Metab       Date:  2003-09       Impact factor: 5.958

7.  Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance.

Authors:  Haiyan Xu; Glenn T Barnes; Qing Yang; Guo Tan; Daseng Yang; Chieh J Chou; Jason Sole; Andrew Nichols; Jeffrey S Ross; Louis A Tartaglia; Hong Chen
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

8.  Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension.

Authors:  Masato Furuhashi; Nobuyuki Ura; Katsuhiro Higashiura; Hideyuki Murakami; Marenao Tanaka; Norihito Moniwa; Daisuke Yoshida; Kazuaki Shimamoto
Journal:  Hypertension       Date:  2003-06-09       Impact factor: 10.190

Review 9.  Lipid inflammatory mediators in diabetic vascular disease.

Authors:  Rama Natarajan; Jerry L Nadler
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-05-27       Impact factor: 8.311

10.  The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity.

Authors:  T Yamauchi; J Kamon; H Waki; Y Terauchi; N Kubota; K Hara; Y Mori; T Ide; K Murakami; N Tsuboyama-Kasaoka; O Ezaki; Y Akanuma; O Gavrilova; C Vinson; M L Reitman; H Kagechika; K Shudo; M Yoda; Y Nakano; K Tobe; R Nagai; S Kimura; M Tomita; P Froguel; T Kadowaki
Journal:  Nat Med       Date:  2001-08       Impact factor: 53.440

View more
  37 in total

Review 1.  Functional and pathological roles of the 12- and 15-lipoxygenases.

Authors:  Anca D Dobrian; David C Lieb; Banumathi K Cole; David A Taylor-Fishwick; Swarup K Chakrabarti; Jerry L Nadler
Journal:  Prog Lipid Res       Date:  2010-10-21       Impact factor: 16.195

2.  Functional role of sodium glucose transporter in high glucose-mediated angiotensin type 1 receptor downregulation in human proximal tubule cells.

Authors:  Rekha Yesudas; Russell Snyder; Thomas Abbruscato; Thomas Thekkumkara
Journal:  Am J Physiol Renal Physiol       Date:  2012-05-30

3.  Weight loss and hypophagia after high-dose AT1-blockade is only observed after high dosing and depends on regular leptin signalling but not blood pressure.

Authors:  Helge Müller-Fielitz; Antonie Markert; Christian Wittmershaus; Friedrich Pahlke; Olaf Jöhren; Walter Raasch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-02-03       Impact factor: 3.000

Review 4.  Interaction between cytokines and inflammatory cells in islet dysfunction, insulin resistance and vascular disease.

Authors:  Y Imai; A D Dobrian; J R Weaver; M J Butcher; B K Cole; E V Galkina; M A Morris; D A Taylor-Fishwick; J L Nadler
Journal:  Diabetes Obes Metab       Date:  2013-09       Impact factor: 6.577

Review 5.  The central role of calcium in the effects of cytokines on beta-cell function: implications for type 1 and type 2 diabetes.

Authors:  James W Ramadan; Stephen R Steiner; Christina M O'Neill; Craig S Nunemaker
Journal:  Cell Calcium       Date:  2011-09-23       Impact factor: 6.817

Review 6.  Immunologic and endocrine functions of adipose tissue: implications for kidney disease.

Authors:  Qingzhang Zhu; Philipp E Scherer
Journal:  Nat Rev Nephrol       Date:  2017-12-04       Impact factor: 28.314

Review 7.  The renin angiotensin aldosterone system and insulin resistance in humans.

Authors:  Patricia C Underwood; Gail K Adler
Journal:  Curr Hypertens Rep       Date:  2013-02       Impact factor: 5.369

8.  STAT4 contributes to adipose tissue inflammation and atherosclerosis.

Authors:  A D Dobrian; M A Hatcher; J J Brotman; E V Galkina; P Taghavie-Moghadam; H Pei; B A Haynes; J L Nadler
Journal:  J Endocrinol       Date:  2015-08-18       Impact factor: 4.286

Review 9.  The role of renin-angiotensin agents in altering the natural history of type 2 diabetes mellitus.

Authors:  Joel A Lardizabal; Prakash C Deedwania
Journal:  Curr Cardiol Rep       Date:  2010-11       Impact factor: 2.931

10.  Diabetes mellitus and vascular disease.

Authors:  James R Sowers
Journal:  Hypertension       Date:  2013-05       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.